Please confirm that you would like to log out of Medscape.
If you log out, you will be required to enter your username and password the next time you visit.
Log outCancel
European Association for the Study of Diabetes (EASD) 2016 Annual Meeting
September 12 - 16, 2016; Munich Germany
September 12 - 16, 2016Munich Germany
Medscape at Booth S.05
EASDHalf of All Type 1 Diabetes Develops After 30 Years of Age UK researchers find equal distribution of autoimmune-mediated diabetes below and above age 30 years, but after 30 this is "spotting a needle in a haystack," as cases are far exceeded by type 2 diabetes.
Medscape Medical News, September 20, 2016
EASDLibre 'Flash' Glucose Monitoring System Cuts HypoglycemiaExperts weigh the relative pros and cons of the new Freestyle Libre "Flash" Glucose Monitoring System, which seems to be gaining in popularity among diabetes patients in Europe.
Medscape Medical News, September 20, 2016
EASDFirst Data on GLP-1 Agonist/SGLT2 Inhibitor Combo in Diabetes Exenatide once weekly combined with daily dapagliflozin improved glycemic outcomes, BP, and weight loss more than each drug alone in DURATION-8, the first trial to examine a combination of these 2 agents.
Medscape Medical News, September 19, 2016
Meeting Highlights At A Glance
Top News From EASD 2016: SlideshowHighlights include the first full presentation of data from the SUSTAIN-6 trial plus renal results from LEADER and "eye-opening"
data on type 1 diabetes.
After EMPA-REG: Docs Dissect Diabetes Study, Discuss ImplicationsDoctors tried to make sense of the "unique" finding of the EMPA-REG OUTCOME study, which showed a mortality benefit for empagliflozin,
but admitted the trial posed more questions than it answered.
Medscape Medical News, Sep 24, 2015
Capsaicin Patch Approved in EU for Diabetic Neuropathy PainA capsaicin patch has been approved in the EU for use in diabetic neuropathy; a study reported at the EASD meeting showed
the patch relieved pain and improved sleep among such patients.
Medscape Medical News, Sep 21, 2015
Home Use of 'Artificial Beta Cell' Works for 3 MonthsAn "artificial beta-cell" system using already-available pumps and sensors improved glycemic control and reduced hypoglycemia
in adults and children for 3 months in unrestricted and unsupervised real-world settings.
Coverage of key advances and expert reactions as they happened at the meeting.
Medscape Board at the Podium
Per-Henrik Groop, MD, DMSc Helsinki University Central Hospital, Finland Presentation: OP 07 Novel insights into diabetic nephropathy Date: September 13, 2016 Presentation: OP 11 Novel approaches to unravel glucose homeostasis in humans Date: September 13, 2016 Presentation: OP 35 Novel genetics discoveries and phenotypic characterization Date: September 15, 2016 Presentation: OP 36 Biomarkers and predictors of diabetic nephropathy Date: September 15, 2016
Simon Heller, MB BChir, DM, FRCP University of Sheffield School of Medicine; South Yorkshire, United Kingdom Presentation: OP 02 insulin insights Date: September 13, 2016 Chair of the Session: OP 14 Hypoglycaemia: The low down Date: September 14, 2016
Arya Sharma, MD, PhD PS 038 Determinants of beta cell function in humans and in non-human Primates Presentation: PS 038 Determinants of beta cell function in humans and in non-human Primates Date: September 13, 2016